Elicio Therapeutics, Inc. — Form 8-K
Filed July 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Elicio Therapeutics sold 4,380,313 common shares at $3.43 per share for ~$15M gross proceeds (before fees) in a registered direct offering to institutional investors on July 1, 2026, with closing expected July 6, 2026. Proceeds will fund Phase 1 development of ELI-002 7P in metastatic pancreatic cancer and pipeline work. Placement agents: Titan Partners Group (lead, 70% of 7% fee) and B. Riley Securities (30% of fee).
Why this rating
Financing is ~18% of $81.8M market cap, material for runway, but typical for clinical-stage biotech. No immediate business threat or transformation.
Extracted items
- 1.01 material agreement
- 8.01 other event
- 9.01 exhibits
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.